로딩 중…
지수 로딩 중…
JEIL PHARMACEUTICAL CO.,LTD
271980· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩8,730+1.51%
2026-11-02
Financials
Valuation Metrics
JEIL PHARMACEUTICAL CO.,LTD's Market Cap is ₩1284B. At end of 2025 it was ₩2228B. Ranked #1063 of 2,405 in KR market (top 44%), #519 of 778 on KOSPI (top 67%), #124 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 128.37B KRW | KR#1,063/2,405 Sec#124/231 |
| Revenue | 543.49B KRW | KR#589/2,405 Sec#30/231 |
| Net Income | 21.89B KRW | KR#671/2,405 Sec#45/231 |
| Total Assets | 526.12B KRW | KR#750/2,405 Sec#44/231 |
| Net Assets | 253.26B KRW | KR#820/2,405 Sec#54/231 |
| Employees | 983 | KR#260/2,405 Sec#20/231 |
| Value | ||
| P/E | 5.87x | KR#502/2,405 Sec#22/231 |
| P/B | 0.51x | KR#887/2,405 Sec#45/231 |
| P/S | 0.24x | KR#503/2,405 Sec#10/231 |
| EV/EBITDA | 48.13x | KR#1,352/2,405 Sec#87/231 |
| FCF Yield | -10.69% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 8.64% | KR#725/2,405 Sec#51/231 |
| ROA | 4.16% | KR#835/2,405 Sec#68/231 |
| Op. Margin | 0.69% | KR#1,536/2,405 Sec#108/231 |
| Revenue Growth | -17.85% | KR#2,088/2,405 Sec#192/231 |
| Earnings Growth | -44.84% | KR#1,038/2,405 Sec#68/231 |
| Financial Health | ||
| Debt Ratio | 107.74% | KR#1,612/2,405 Sec#184/231 |
| Total Debt | 109.65B KRW | KR#693/2,405 Sec#42/231 |
| FCF | -13.72B KRW | KR#1,791/2,405 Sec#164/231 |
| Cash | 58.54B KRW | KR#675/2,405 Sec#37/231 |
| Current Ratio | 1.33x | KR#1,339/2,405 Sec#141/231 |
| Net Debt/EBITDA | 13.71x | KR#1,307/2,405 Sec#93/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -39.29% | KR#1,674/2,405 Sec#136/231 |
| 1M Return | -12.70% | KR#1,394/2,405 Sec#138/231 |
| From 52W High | -54.74% | KR#1,384/2,405 Sec#112/231 |
| 1Y MDD | -50.55% | KR#980/2,405 Sec#77/231 |
| Trading | ||
| Volume | 6,251 shares | KR#2,027/2,405 Sec#202/231 |
| Trading Value | 54.0M KRW | KR#1,684/2,405 Sec#178/231 |
| Foreign Own. | 1.65% | KR#1,766/2,405 Sec#172/231 |
| Per Share | ||
| EPS | 1,488 KRW | KR#562/2,405 Sec#39/231 |
| BPS | 17,223 KRW | KR#616/2,405 Sec#40/231 |
Company Info
동사는 2017년 제일파마홀딩스의 전문의약품사업부문이 인적분할되어 설립, 유가증권시장에 재상장했으며 2020년 온코닉테라퓨틱스를 자회사로 두고 있음. 완제 의약품 제조 및 판매를 주사업으로 전문의약품 시장에서 종합병원, 의원, 약국 유통채널을 통해 사업을 추진하고 있음. 지속 성장 위해 내부 연구개발 및 외부 기술 연계를 통한 개방형 혁신과 의료환경 변화에 대응하는 전략적 기반을 강화하고 있음. 제일약품는 2017년에 설립되었으며 서울특별시 서초구에 본사를 두고 있습니다.